SK73794A3 - Stabilized pharmaceutical formulation comprising growth hormone and aspargine - Google Patents

Stabilized pharmaceutical formulation comprising growth hormone and aspargine Download PDF

Info

Publication number
SK73794A3
SK73794A3 SK737-94A SK73794A SK73794A3 SK 73794 A3 SK73794 A3 SK 73794A3 SK 73794 A SK73794 A SK 73794A SK 73794 A3 SK73794 A3 SK 73794A3
Authority
SK
Slovakia
Prior art keywords
growth hormone
hgh
asparagine
deamidation
preparation
Prior art date
Application number
SK737-94A
Other languages
English (en)
Slovak (sk)
Inventor
Hans Sorensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SK73794A3 publication Critical patent/SK73794A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK737-94A 1991-12-20 1992-12-16 Stabilized pharmaceutical formulation comprising growth hormone and aspargine SK73794A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK912047A DK204791D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
PCT/DK1992/000378 WO1993012811A1 (fr) 1991-12-20 1992-12-16 Formulation pharmaceutique stabilisee comprenant une hormone de croissance et de l'asparagine

Publications (1)

Publication Number Publication Date
SK73794A3 true SK73794A3 (en) 1995-03-08

Family

ID=8109696

Family Applications (1)

Application Number Title Priority Date Filing Date
SK737-94A SK73794A3 (en) 1991-12-20 1992-12-16 Stabilized pharmaceutical formulation comprising growth hormone and aspargine

Country Status (19)

Country Link
US (2) US5977069A (fr)
EP (1) EP0618806B1 (fr)
JP (1) JP3662580B2 (fr)
KR (1) KR100270726B1 (fr)
AT (1) ATE177645T1 (fr)
AU (1) AU664416B2 (fr)
BG (1) BG98804A (fr)
CA (1) CA2125856A1 (fr)
CZ (1) CZ282826B6 (fr)
DE (1) DE69228704T2 (fr)
DK (1) DK204791D0 (fr)
FI (1) FI942905A7 (fr)
HU (1) HUT69682A (fr)
NO (1) NO942299L (fr)
NZ (1) NZ246555A (fr)
RO (1) RO112086B1 (fr)
RU (1) RU2098130C1 (fr)
SK (1) SK73794A3 (fr)
WO (1) WO1993012811A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
JPH10511964A (ja) * 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
SK281571B6 (sk) * 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6008256A (en) * 1995-08-28 1999-12-28 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
EP0934061B3 (fr) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba et ses derives utilises pour le traitement de la douleur
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
RU2234945C2 (ru) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Стабилизатор водного раствора и водосодержащего сырья с самопроизвольно изменяющимися окислительно-восстановительными свойствами
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2008073856A2 (fr) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Administration de nanoparticules et/ou d'agents à des cellules
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0303746B2 (fr) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisation des hormones de croissance
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
EP0374120A3 (fr) * 1988-12-13 1991-07-31 Monsanto Company Composition pour la libération contrôlée des polypeptides
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DK0955062T3 (da) * 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation

Also Published As

Publication number Publication date
KR100270726B1 (ko) 2000-11-01
ATE177645T1 (de) 1999-04-15
NO942299D0 (no) 1994-06-17
KR940703689A (ko) 1994-12-12
RO112086B1 (ro) 1997-05-30
JP3662580B2 (ja) 2005-06-22
NZ246555A (en) 1996-03-26
DK204791D0 (da) 1991-12-20
CA2125856A1 (fr) 1993-07-08
RU94045921A (ru) 1996-08-27
CZ282826B6 (cs) 1997-10-15
FI942905L (fi) 1994-06-17
EP0618806B1 (fr) 1999-03-17
AU664416B2 (en) 1995-11-16
DE69228704D1 (de) 1999-04-22
US5977069A (en) 1999-11-02
BG98804A (bg) 1995-02-28
FI942905A0 (fi) 1994-06-17
WO1993012811A1 (fr) 1993-07-08
JPH07502515A (ja) 1995-03-16
HU9401831D0 (en) 1994-09-28
HUT69682A (en) 1995-09-28
RU2098130C1 (ru) 1997-12-10
DE69228704T2 (de) 1999-09-16
FI942905A7 (fi) 1994-06-17
EP0618806A1 (fr) 1994-10-12
AU3344593A (en) 1993-07-28
CZ145894A3 (en) 1994-12-15
NO942299L (no) 1994-06-17
US5851992A (en) 1998-12-22

Similar Documents

Publication Publication Date Title
CZ145894A3 (en) Stabilized pharmaceutical preparation containing growth hormone and asparagin, and the use of such pharmaceutical preparation
AU733592B2 (en) A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
AU715997B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
US5705482A (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
CZ150794A3 (en) Pharmaceutical preparation containing growth hormone and histidine
US8841252B2 (en) Pharmaceutical formulation
EP0785796B1 (fr) Formulation pharmaceutique comportant une hormone de croissance et de l'isoleucine
US5547696A (en) Pharmaceutical formulation
EP0785797B1 (fr) Formulation pharmaceutique comportant une hormone de croissance et de la leucine
US5552385A (en) Pharmaceutical formulation
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
AU699850B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue
US20030162711A1 (en) Pharmaceutical formulation
MXPA98000309A (en) Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac
MXPA98008786A (en) A pharmaceutical formulation containing a growth hormone, an amino acid and a non-ion detergent
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal